PF-06882961 + rosuvastatin

PF-06882961 + rosuvastatin is a combination of two drugs: **danuglipron (PF-06882961)**, an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed for obesity and type 2 diabetes, and **rosuvastatin**, an HMG-CoA reductase inhibitor (statin) widely used for dyslipidemia and cardiovascular risk reduction. Danuglipron acts by agonizing the GLP-1 receptor to promote weight loss and glycemic control[2][4][6]. Rosuvastatin inhibits the HMG-CoA reductase enzyme, reducing cholesterol synthesis and lowering LDL cholesterol, thus reducing cardiovascular events[7]. The combination is investigated primarily to assess possible pharmacokinetic drug-drug interaction (not as a marketed therapeutic product), specifically how danuglipron may affect the metabolism and blood levels of rosuvastatin[1][3].

Other names

danuglipron + rosuvastatin